Reuteri marks 21 years in Hong Kong
Thestandard · 1 SOURCESabout 2 hours ago2 MIN
Summary
BioGaia’s Reuteri brand has marked its 21st anniversary in Hong Kong with an academic symposium and dinner centered on evidence-based applications for functional gastrointestinal disorders, or FGIDs. The event brought together doctors, pharmacists and dietitians to review clinical findings on the L. reuteri DSM 17938 strain.
Key Points
- Reuteri was introduced to Hong Kong in 2005, and J-Health recently held a 21st-anniversary symposium and dinner on October 23 themed “Redefining the Standard: Evidence-based Application of Reuteri in FGIDs.”
- The event drew nearly 100 participants, including doctors from local private hospitals and clinics, community pharmacists and registered dietitians.
- BioGaia said Reuteri was named the No. 1 children’s probiotic supplement brand in Europe and Latin America this year.
- According to the company, the product is backed by more than 302 clinical studies, recommended by 17 international medical guidelines and adopted by multiple private hospitals in Hong Kong.
- BioGaia Chief Scientific Officer Gianfranco Grompone said L. reuteri DSM 17938 is a human-origin strain isolated from the breast milk of a Peruvian mother in the late 1980s, and that BioGaia probiotics have been studied in about 300 randomized controlled trials, most of them double-blind and placebo-controlled.
Why It Matters
For Hong Kong families and healthcare practitioners, the company’s emphasis on clinical evidence and hospital adoption may shape how probiotics are discussed in managing common digestive complaints in children. Functional abdominal pain was described at the event as one of the most common causes of abdominal pain in children, with lasting effects on both children and their families.